Targeting IRFs for Immune Adjuvant Enhancement of Vaccine Immunogenicity in West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus vaccines

佐剂发现计划支持疫苗新型候选佐剂的早期发现和初步表征。研究必须包括：（1）通过高通量筛选（HTS）方法鉴定新型佐剂候选物，并验证先导化合物刺激人类细胞;（2）确定选定先导化合物的作用机制，包括鉴定佐剂候选物通过的受体及其激活的细胞信号传导途径;（3）在结构-活性关系（SAR）研究的指导下，通过制剂和药物化学优化先导候选物;和（4）在动物模型中验证先导化合物作为疫苗佐剂的体内功效。 项目必须包括动物模型研究，以测试候选佐剂与疫苗对： A）一种或多种NIAID新发和再发传染病病原体（http：//www.niaid.nih.gov/topics/emerging/pages/default.aspx），或 B）一种或多种NIAID新发和再发传染病病原体以及一种或多种与人类疾病相关的其它（非HIV）病原体。

The Adjuvant Discovery Program supports the early stage discovery and initial characterization of novel adjuvant candidates for vaccines. The research must include (1) identification of novel adjuvant candidates through high throughput screening (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the mechanism of action of select lead compounds, including the identification of the receptor(s) the adjuvant candidates work through and the cellular signaling pathways they activate; (3) optimization of lead candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of the efficacy of lead compounds as vaccines adjuvants in vivo in an animal model. Projects must include animal model studies to test the adjuvant candidates with vaccines against: A) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens http://www.niaid.nih.gov/topics/emerging/pages/default.aspx), or B) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens as well as one or more other (non-HIV) pathogens relevant to human disease.